Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INL1 (trientine) in heart failure with reduced ejection fraction
CTR20211406Phase 2Active
- Sponsor
- CopMed，Inc./ 方达医药技术有限公司/ 成都因诺生物医药科技有限公司
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trientine in heart failure with reduced ejection fraction (HFrEF), sponsored by CopMed，Inc./ 方达医药技术有限公司/ 成都因诺生物医药科技有限公司. Started Jul 2021; status: active.
02
Drugs
trientine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20211406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211406.